• Kun-Feng Tsai, Jerry C H Tsai, Ming-Feng Li, Jimmy W H Tan, Chu-Kuang Chou, Huei-Lung Liang, and Shan-Ho Chan.
• Gastroenterology and Hepatology Section, Department of Internal Medicine, An Nan Hospital, China Medical University, Tainan 709, Taiwan.
• Medicina (Kaunas). 2021 Aug 20; 57 (8).

AbstractBackground: Until recently, advanced HCC patients with major vessel and cardiac involvement have had an extremely poor prognosis without satisfactory treatment. Case presentation: A 63-year-old Taiwanese male presented with metastatic HCC with RA and IVC thrombi, as well as pulmonary metastases that were successfully treated by multimodal management, encompassed by surgical thrombectomy, concurrent systemic sorafenib and locoregional therapies, and immunotherapy. The patient has achieved a complete response over the past 33 months. Conclusions: Through this case report, which shows a successful outcome via multimodal management, a more aggressive approach should be considered when a patient is expected to tolerate the risks and side effects of various treatments.

14 keywords...

hide…